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Abstract
Schistosomiasis is caused by several worm species of the genus Schistosoma and afflicts up to 600 million people in 74
tropical and sub-tropical countries in the developing world. Present disease control depends on treatment with the only
available drug praziquantel. No vaccine exists despite the intense search for molecular candidates and adjuvant
formulations over the last three decades. Cysteine peptidases such as papain and Der p 1 are well known environmental
allergens that sensitize the immune system driving potent Th2-responses. Recently, we showed that the administration of
active papain to mice induced significant protection (P,0.02, 50%) against an experimental challenge infection with
Schistosoma mansoni. Since schistosomes express and secrete papain-like cysteine peptidases we reasoned that these could
be employed as vaccines with inbuilt adjuvanticity to protect against these parasites. Here we demonstrate that sub-
cutaneous injection of functionally active S. mansoni cathepsin B1 (SmCB1), or a cathepsin L from a related parasite Fasciola
hepatica (FhCL1), elicits highly significant (P,0.0001) protection (up to 73%) against an experimental challenge worm
infection. Protection and reduction in worm egg burden were further increased (up to 83%) when the cysteine peptidases
were combined with other S. mansoni vaccine candidates, glyceraldehyde 3-phosphate dehydrogenase (SG3PDH) and
peroxiredoxin (PRX-MAP), without the need to add chemical adjuvants. These studies demonstrate the capacity of helminth
cysteine peptidases to behave simultaneously as immunogens and adjuvants, and offer an innovative approach towards
developing schistosomiasis vaccines
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Introduction
Schistosomiasis, also known as bilharzia, infects between 391
and 600 million people in 74 developing countries in the tropics
and sub-tropics, and close to 800 million, mostly children, are at
risk [1]. Disease burden is estimated to exceed 70 million
disability-adjusted life-years (DALYS) [2] and leads to remarkably
high years lived with disability (YLD) rates [3]. The causative
agents are several dioecious (separate sex) trematodes, of the family
Schistosomatidae, most notably Schistosoma mansoni, S. haematobium
and S. japonicum [1,2]. Infective aquatic larvae, known as cercariae,
invade host skin and develop into schistosomula by exchanging
their classical outer membrane for a unique double lipid bilayer as
they make their way to the dermal blood vessels [4]. Schistosomula
travel via the pulmonary artery to the lungs over 4–6 days before
entering the pulmonary capillaries and migrating to the hepatic
portal and then to the mesenteric blood vessels. Here, the parasites
mature and copulate for their entire life and acquire nutrients from
blood to support the production of numerous eggs [5]. There is
only one drug available to treat schistosomiasis, praziquantel, and
thus the possible emergence of drug resistant parasites could have
disastrous public health consequences [1,2].
Over the last three decades in particular, intense research efforts
have been devoted to the discovery of vaccine candidates, a
process greatly facilitated by the availability of schistosome
proteomic, transcriptomic, and genomic databases [6,7,8]. Vac-
cine trials in mice using various schistosome molecules have
demonstrated that significant (P,0.05–,0.02) and reproducible
reduction of 30–50% in challenge worm burden can be achieved
[9–13] although no clear consensus has been reached as to the
phenotype of immune response required for protection. In our
previous studies we showed that during acute natural infection of
mice, schistosomula-secreted antigens glyceraldehyde 3-phosphate
dehydrogenase (SG3PDH) and peroxiredoxin-multiple antigen
peptide (PRX-MAP) elicit predominantly Th1 and Th17 immune
responses, characterized by the production of interferon-gamma
(IFN-c) and interleukin (IL)-17, and IgG2a and IgG2b antibodies
[14]. We found that immunization of mice with SG3PDH or
PRX-MAP alone or emulsified with Freund’s, alum, or Allison’
adjuvant failed to elicit protection in mice against challenge
infection. In contrast, SG3PDH/PRX-MAP combined with the
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type 2 cytokines, thymic stromal lymphopoietin (TSLP), IL-25,
and IL-33 [15], switched the antigen specific response elicited
during a challenge infection towards a Th2 phenotype. Circulating
antigen-specific antibodies were primarily of the IgG1 isotype and
spleen cells stimulated ex vivo, secreted parasite-antigen specific
IL-4, IL-5 and IL-13. This alteration in the immune response
induced by parasite antigens correlated with high and significant
(up to P,0.0001) reduction of 62% (TSLP) to 78% (IL-33) in
challenge worm burden [16].
Similarly, we discovered that switching the parasite-specific
immune response towards a Th2 phenotype by a sub-cutaneous
injection of the plant cysteine peptidase papain to mice prior to a
challenge infection with S. mansoni conferred 50% protection [16].
Papain and other environmental allergens such as ficin, bromelain,
and Der p 1 are members of the C-1 peptidases family and their
proteolytic activity is believed to be necessary for the adjuvant-like
induction of Th2-mediated responses [17–20]. Schistosomes
express several members of the C-1 peptidases, including
cathepsins B (SmCB) and cathepsins L (SmCL) that are known
to play critical roles in the digestion of host blood tissues and
hemoglobin (SmCB1, SmCL1, SmCL3), in reproduction (SmCL2)
and surface tegument biogenesis (SmCB2) [7,21–27]. We reasoned
that these schistosome peptidases besides being likely vaccine
targets may also, because of their intrinsic proteolytic activity,
possess inbuilt adjuvant properties that could enhance their
efficacy.
Here we show that sub-cutaneous immunization of outbred
mice with functionally active forms of recombinant SmCB1, or a
cathepsin L from the related trematode parasite Fasciola hepatica
(FhCL1) induce highly significant (P,0.0001) and reproducible
reduction of 50–73% in challenge worm burdens, and in liver and
intestinal egg burdens. Blocking of SmCB1 activity with an
irreversible inhibitor prior to delivery or use of an enzymatically
inactive FhCL1 mutant molecule significantly (P,0.0001) re-
duced, but did not ablate, the protective properties of the
peptidase. Higher levels of protection levels (.80%) were attained
when either SmCB1 or FhCL1 were delivered in combination
with other vaccine candidates, namely SG3PDH/PRX-MAP.
These studies demonstrate the capacity of parasite C-1 cysteine
peptidases to behave simultaneously as immunogens and adju-




The patient study was approved by the Institution Ethics
Review Board of the National Liver Institute, Menoufiya
University. All donors of serum samples were adults and provided
both verbal and written consent which was also reviewed and
approved by the Institution Ethics Review Board and is now
stored at Cairo University, Egypt. Studies on mice were approved
by the Animal Care and Use Committee of the Theodore Bilharz
Research Institute, Giza, Egypt.
Mice and parasites
Cercariae of an Egyptian strain of S. mansoni were obtained from
the Schistosome Biological Materials Supply Program, Theodore
Bilharz Research Institute (SBSP/TBRI), Giza, Egypt, and used
for infection immediately after shedding from Biomphalaria
alexandrina snails. Outbred, female, six-week-old CD1 mice were
raised at SBSP/TBRI, and housed throughout experimentation in
the Animal Facility of the Faculty of Science, Cairo University.
Every effort was made to minimize animal suffering including
change of bedding three times per week, clean, air-conditioned
and quiet housing, delicate handling on injection, exposure to
infection, and euthanizing, and no extension of experiments
beyond seven weeks after infection. All animal experiments were
performed following the recommendations of the current edition
of the Guide for the Care and Use of Laboratory Animals,
Institute of Laboratory Animal Resources, National Research
Council, Washington, DC.
Immunogens
Functionally active S. mansoni cathepsin B1 (SmCB1) and
Fasciola hepatica cathepsin L1 (FhCL1) were expressed in the yeast
Pichia pastoris GS115 strain using the pPIC9K vector; enzyme
activity was assessed by the hydrolysis of 7-amino-4-methyl
coumarin (NHMec) from the fluorogenic peptide substrate Z-
Phe-Arg-NHMec [28,29]. The production of the FhCL1 enzy-
matically inactive variant FhCL1Gly26 (Cys26 to Gly26, mFheCL1)
used in this study was described before [29,30]. Potential N-
glycosylation sites where removed from the peptidases cDNAs by
mutation so that expressed recombinant did not bear yeast glycans
[28–31]. The recombinant enzymes were produced by fermenta-
tion at 30uC and 250 rpm in 1 liter buffered glycerol-complex
medium (BMGY) broth buffered to pH 6.0 into 4 liter baffled
flasks until achieving an OD600 of 2–6. The cells were centrifuged
at 3,0006 g for 10 min at room temperature and induction
initiated by resuspending the pellets in 200 ml BMMY broth and
adding 1% of 100% filter–sterilized methanol every 24 h for 3
days. The culture was then centrifuged at 16,0006g for 30 min at
room temperature and proteases isolated from the supernatant by
Ni-NTA affinity chromatography [28,30]. SmCB was inactivated
by incubation for 30 min at room temperature in the presence of
5 mM of the irreversible inhibitor of cysteine peptidases, L-trans-
epoxysuccinylleucylamide-(4-guanido)-butane (E-64, Calbiochem),
as described [32].
Recombinant S. mansoni glyceraldehyde 3-phosphate dehydro-
genase (SG3PDH) was prepared and purified to homogeneity, as
described [33], and contained ,0.06 Endotoxin Units/ml as
judged by the Pyrogen Gel-Clot Limulus Amebocyte Lysate test
(Bio-Whittaker). 2-Cys peroxiredoxin [34] (H-104RKQEIS-
KAYGVFDE EDGNA122-OH)-derived peptide, showing lowest
homology to the murine counterpart, was synthesized as a tetra
branched multiple antigen peptide (MAP) construct and purified
at AnaSpec, Inc. (San Jose, California). Schistosoma mansoni soluble
egg antigen (SEA) was prepared as described [35].
Mouse immunization and infection
Mice (10–14 per group) were immunized subcutaneously at the
base of the tail with 10 or 20 mg SmCB1 or FhCL1 alone or in a
mixture, or combined with rSG3PDH and PRX MAP (10 mg/
mouse), twice (unless otherwise stated) at 3-week interval. Two
(unless otherwise stated) weeks after the last injection, unimmu-
nized and immunized mice were infected percutaneously via
whole body exposure to 12065 (Experiments 1, 2, 3, 6 and 7) or
14065 (Experiments 4 and 5) viable cercariae of S. mansoni.
Recovery of lung-stage schistosomula
For each experiment, lung-stage schistosomula were recovered
from 2–3 mice per group on day 6 post infection, as described
[36], and counted on an individual mouse basis.
Spleen cell cultures and cytokine assays
Spleen cells (SC) were harvested from 2–3 mice per group per
experiment on day 6 after infection with S. mansoni cercariae, and
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resuspended on an individual mouse basis in RPMI-1640 medium
supplemented with 200 U/ml penicillin, 200 mg/ml streptomycin,
25 mM HEPES, 50 ng/ml amphotericin, 20 mg/ml polymyxin B
(Sigma) as an inhibitor of any residual lipopolysaccharide
contamination of recombinant antigens, 561025 M 2-mercapto-
ethanol, and 10% fetal calf serum (culture medium) [14,16].
Splenocytes were cultured at a concentration of 16106 cells/
200 ml culture medium/well in duplicate wells of 96 round-
bottomed well plates (Corning Costar), stimulated with 0 or 5 mg/
ml membrane filter (0.45 mm)-sterilized immunogen, and main-
tained at 37uC in a humidified atmosphere containing 3.0% CO2.
At 48 and 72 h of incubation, cultured SC were thawed and
frozen for release of intracellular cytokines, and supernatants
stored at 276uC until assayed by capture enzyme-linked
immunosorbent assay (ELISA) for concentrations of IL-4, IL-5,
IL-17A, and IFN-c (ELISA MAXTM Set, BioLegend) and IL-13
(DuoSet ELISA Development System, R&D Systems Europe)
following the manufacturer’s instructions.
Mouse humoral responses
Sera were obtained from unimmunized and immunized mice 6
days following infection with cercariae of S. mansoni, and
individually assessed by ELISA for humoral antibody titer
reactivity to the immunogens (250 ng per well). For each
experiment, antibody isotypes were determined using rat alkaline
phosphatase-conjugated monoclonal antibodies to mouse IgG
subclasses (Pharmingen) with mouse sera diluted 1:200, and biotin-
labeled monoclonal antibody to mouse IgM, IgA, and IgE
(BioLegend) with sera diluted 1:50, as described [16].
Worm and worm egg recovery
Worm burden and liver and intestine worm egg load in
individual mice (7 to 11 per group) were evaluated 40–49 days
after challenge infection, as described [37]. Mean values 6 SD for
each group were calculated. Percent change was evaluated by the
formula: % change =mean number in infected controls2mean
number in infected, immunized mice/mean number in infected
controls6100.
Human serum samples and antibody isotype reactivity
Serum samples were obtained from 50 patients, 18–20 year-old,
attending the outpatient clinic of the National Liver Institute,
Menoufiya University, Egypt, and requesting parasite infection
diagnosis. For each donor, two microscopic slides of stool samples
were examined on 3 consecutive days by the Kato-Katz method,
as described [33]. Informed consent was obtained from each
patient with confirmed schistosomiasis (100–400 eggs per gram
stool). Sera from parasite-free and S. mansoni-infected donors were
tested by ELISA for IgM, IgG1, IgG2 (serum diluted 1:250), IgG4,
IgA1/A2, and IgE (serum diluted 1:25) antibody binding to
250 ng/well recombinant SmCB1, FhCL1, SG3PDH, or 1 mg/
well SEA. Alkaline phosphatase- or biotin-labeled monoclonal
antibodies to human immunoglobulin isotypes were obtained from
BD Biosciences (Franklin Lakes, New Jersey), and used at 1:1000,
and 1:500 dilution, respectively. Alkaline phosphatase-labeled
streptavidin was purchased from Promega (Madison, Wisconsin),
and used at 1:3000 dilution.
Data analysis and statistics
All values were tested for normality. Student’s unpaired 2-tailed
t-test, Mann–Whitney, and ANOVA tests were used to analyze the
statistical significance of differences between experimental and
control values and considered significant at P,0.05.
Results
Vaccination against murine schistosomiasis with C-1
cysteine peptidases
The major C-1 cysteine peptidase of the blood fluke S. mansoni,
SmCB1, was expressed as a functionally-active recombinant
enzyme using the yeast Pichia pastoris as the surrogate host. The
enzyme was purified to homogeneity by Nickel-affinity chroma-
tography and was injected (10 mg) subcutaneously into mice
(number = 10–14) either once, or twice with a two-week interval.
Two weeks later the mice were infected with S. mansoni cercariae
and worm burden assessed 40–49 days post infection. Adminis-
tration of parasite C-1 peptidase induced highly significant (P,
0.0001) reduction (.60%), in total (Figures 1a,b), and male and
female challenge worm burden, accompanied with significant (P,
0.005) decrease in worm egg counts in liver, but not small intestine
(Table 1).
In confirmatory experiments, using two immunizations of
different doses of SmCB1, 10 mg (Fig. 1d) or 20 mg (Figure 1e),
injection of active peptidase induced a protection level of 60% and
73%, respectively. Furthermore, to determine whether the
protective properties of the SmCB1 were dependent on its
proteolytic activity we performed immunizations with SmCB1
that had been incubated with the irreversible covalent C-1
peptidase inhibitor E- 64 just prior to injection into mice; this
treatment significantly (P,0.0001) reduced the vaccine efficacy to
42% (Fig. 1d) and 21% (Figure 1e), respectively, although these
proved to be still statistically significant (P,0.0001; P=0.0023)
when compared to non-vaccinated infected mice.
To verify that this immune protection is a generic property of
C-1 peptidases we also tested a functionally-active cathepsin L
peptidase (FhCL1) derived from another trematode, the liver fluke
F. hepatica. Subcutaneous injection of this peptidase induced highly
significant (P,0.0001) levels of protection of 60% (Figure 1c) and
decrease in liver but not small intestine worm egg load (Table 1).
The data were confirmed in two subsequent experiments showing
protection of 42% and 51% (Figures 1d,e) against a challenge S.
mansoni infection, achieved with 10 mg or 20 mg doses, respectively.
A non-functionally active but structurally sound mutant of FhCL1
(mFhCL1) [29,30] induced protection of only 24% (P,0.0001)
and 14% (P=0.0013) (Figures 1d,e). Differences in mean worm
burden between mice immunized with active and inactive FhCl
(Figures 1d,e) are highly significant (P,0.0001), indicating that
protection with this peptidase was also associated with its cysteine
peptidase activity.
A mixture of SmCB1 and FhCL1 (10 mg each per injection)
induced 63% and 70%, reduction in worm burden, respectively
(Figures 1d,e), which was not significantly different to using
SmCB1 alone, but elicited highly significant (P,0.005) reduction
in worm egg load in liver and small intestine (data not shown).
Accordingly, the collective data show that subcutaneous delivery of
functionally active worm C-1 peptidases alone, or as mixtures, can
induce consistent and high levels of protection in mice against a
challenge infection with cercariae of S. mansoni.
Cysteine peptidases immunogenicity
Mice infected with S. mansoni produced low levels of SmCB-
specific IgG six days after infection, the titre of which was
significantly enhanced in mice pre-immunized with SmCB1
(Figure 2a). In contrast, the increase in peptidase-specific IgG in
mice immunized with inactivated SmCB1 was not significant,
perhaps reflecting the reduced level of protection seen in these
animals compared to vaccination with SmCB1. The titre of
SmCB1 antibody observed in infected mice, pre-immunized with a
Cysteine Peptidase Vaccines
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combination of SmCB1 and FhCL1 was similar to that induced by
SmCB1 alone, mirroring the protective efficacy (Fig. 2a). Infected
mice that had been vaccinated with FhCL1 produced a similar
titre of peptidase-specific IgG to that of mice immunized with
inactivated SmCB1 (Figure 2a), which again correlates with the
similar levels of protection observed in these particular groups.
These peptidase-specific antibodies were of the IgG1 and IgG2b
isotypes (Figure 2b), indicating bias towards a Th2 type immune
response [38], despite the larval antigens induction of predomi-
nant Th1 and Th17 immune responses at 6 days after infection
[14].
In support of the antibody data, mice infected with S. mansoni
that had been pre-immunized with S. mansoni peptidase SmCB1,
developed a Th2-type antigen specific immune response. Spleen
Figure 1. Cysteine peptidases vaccine potential. Mice were immunized 1x (a) or 2x (b–e) with 10 (a–d) or 20 (e) mg active (a–e) or inactive (d,e)
cysteine peptidase/mouse/injection, alone (a–e) or in a mixture (d,e), and exposed 15 days later to 120 (a–c) or 140 (d,e) S. mansoni cercariae.
Columns represent mean worm burden in 7–14 mice/group, and vertical bars denote SD about the mean. P values and percent reduction in worm
burden as compared to control mice are shown above the columns of the test groups. Differences in mean worm burden between mice immunized
with active and inactive cysteine peptidases (d,e) are highly significant (P,0.0001).
doi:10.1371/journal.pone.0085401.g001
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cells obtained from these mice showed increased secretion of Th2-
associated cytokines IL-4, IL-5, IL-13 but not Th1 type cytokine
IFN-c in response to stimulation with SmCB1 in vitro (Figure 2c).
The amount of cytokines secreted from spleen cells isolated from
mice vaccinated with either inactive SmCB1 or FhCL1, the least
protective preparations, was below the sensitivity threshold of the
cytokine assay used, and thus no different to spleen cells harvested
from non-immunized, infected mice (data not shown). In contrast,
the mixture of both FhCL1 and SmCB1, induced a mix of Th1
and Th2 type peptidase-specific cytokines, although the overall
levels of IL-4, IL-5 and IL-13 are higher than IFN-c, indicating a
bias towards a Th2 phenotype (Figure 2c).
Parasite cysteine peptidases act as adjuvants for
schistosome vaccine candidates
We investigated whether C-1 peptidases could act as adjuvants
in combination with other schistosome vaccine candidates
(Table 1). We chose the antigen mix of SG3PDH and PRX-
MAP that was previously shown to induce less than 10%
protection in mice when delivered alone or in combination with
Freund’s, Allison’s or alum adjuvant, but elicited 62–78%
reduction in challenge worm burden and worm eggs when
combined with Th-2 inducing cytokines [16]. In the first
experiment, a single immunization of SmCB1 alone induced a
protection level of 60% (P,0.0001), while the addition of the
SG3PDH/PRX-MAP antigens increased protection to 84% (P,
0.0001). In a second experiment, two immunizations with SmCB1
resulted in a protection level of 66% (P,0.0001) while inclusion of
the SG3PDH/PRX-MAP antigens elicited a protection level of
75% (P,0.0001) (Table 1). Addition of the SG3PDH/PRX-MAP
antigens to FhCL1 peptidase also increased the protection levels,
in this case from 60% to 73% (Table 1). In all trials, highly
significant (P=0.0096–,0.0001) reductions in worm egg burden
in liver and small intestine were achieved, yet with values lower
than for the worm burden (Table 1).
In two experiments, mice were immunized once (Figure 3a) or
twice (Figure 3b) with a mixture of functionally active SmCB1 and
FhCL1 in combination with the SG3PDH/PRX-MAP antigens.
Protection levels were not boosted beyond using C-1 peptidase
alone (Figure 3, Table 1) but we observed very high reductions
(P,0.0001) of 58–69% in the number of eggs recovered from the
liver and small intestine of the challenged mice (Table 1).
To obtain information regarding the stage of development at
which the C-1 peptidases vaccine may operate, a number of mice
from each group were sacrificed 6 days following the challenge
infection and the lungs examined for migrating immature
parasites. No attrition of challenge worms was apparent at this
time as the number of schistosomula recovered from the lungs did
not differ between unimmunized and immunized mice (Table 2).
Interestingly, examination of the lungs at 6 days after infection
indicated that the combined vaccine of SmCB1 and SG3PDH/
PRX-MAP elicited significant protection against the early
migratory stages of the parasite (Table 2).
Human antibody isotype responses
In order to examine whether helminth cysteine peptidases
induce allergenic reactions we examined the humoral responses to
SmCB1 and FhCL1 in parallel toSG3PDH and SEA, during
natural infection in humans. Antibody analysis of sera obtained
from 50 patients with patent schistosomiasis revealed that
antibodies binding to SmCB1, FhCL, or rSG3PDH were
essentially of the IgG2, IgG4, and IgA isotypes with little IgM,
IgG1, and IgE. Conversely, antibodies binding to SEA were
predominantly of the IgM, IgG2, IgG4 and IgE isotype (Figure 4).
Discussion
Our previous studies have shown that immunization with larval
excretory-secretory products (ESP) in a recombinant or multiple
antigen peptide (MAP) construct in combination with the cysteine
protease papain or the type 2 cytokine, TSLP, IL-25, or IL-33
consistently induced highly significant (P,0.0001) reduction of
60–78% in challenge S. mansoni worm burden and worm egg load
in liver and small intestine of outbred mice [16]. Since helminth
cysteine peptidases are both ESP [21–23] and potentially type 2
immune responses-inducing [17,20], it was reasonable to assess the
adjuvant-free vaccine potential of the cysteine peptidases SmCB,
Table 1. Protective effects of immunization with C-1 peptidases SmCB1 and FhCL1 alone and in combination with SG3PDH/PRX-
MAP on male and female worm burdens and parasitological parameters.







1. Single immunization SmCB1 60.05 (,0.0001) 60.29 (,0.0001) 59.57 (,0.0001) 26.63 (,0.0041) 26.01 (,0.018)
SmCB1&SG3PDH/PRX-MAP 83.79 (,0.0001)a 88.23 (,0.0001) 82.44 (,0.0001) 54.68 (,0.0001) 37.58 (0.0006)
2. Two immunizations SmCB1 66.19 (,0.0001) 65.88 (,0.0001) 66.55 (,0.0001) 51.30 (,0.0007) 24.71 (NS)
SmCB1&SG3PDH/PRX-MAP 75.00 (,0.0001) 74.1 (,0.0001) 75.60 (,0.0001) 58.44 (0.0002) 41.24 (0.0096)
3. Two immunizations FhCL1 60.40 (,0.0001) 60.67 (,0.0001) 59.89 (,0.0001) 34.99 (,0.0007) 24.05 (NS)
FhCL1&SG3PDH/PRX-MAP 73.43 (,0.0001) 73.78 (,0.0001) 72.91 (,0.0001) 60.10 (,0.0001) 49.38 (,0.0001)
4. Single immunization SmCB1&FhCL1&SG3PDH/PRX-MAP 56.45 (,0.0001) 52.84 (,0.0001) 61.73 (,0.0001) 58.84 (,0.0001) 65.0 (,0.0001)
5. Two immunizations SmCB1&FhCL1&SG3PDH/PRX-MAP 66.39 (,0.0001) 66.66 (,0.0001) 65.97 (,0.0001) 65.97 (,0.0001) 69.32 (,0.0001)
Mice (10–12/group) were immunized with SmCB1 or FhCL1 combined with rSG3PDH/PRX-MAP and challenged 2 (panels 1–3) or 3 (panels 4 and 5) weeks after the last
immunization.
*Percent reduction was evaluated by the formula: % reduction =mean number in infected controls2mean number in infected, immunized mice/mean number in
infected controls6100.
aP values as calculated by Student 2-tailed t-test. NS = not significant.
doi:10.1371/journal.pone.0085401.t001
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and FhCl, which shows 60% homology with the S. mansoni
counterpart.
We here demonstrate that the sub-cutaneous administration of
functionally active S. mansoni C-1 peptidase, SmCB1, to mice elicits
consistent and remarkably high levels protection against a
challenge infection of the S. mansoni parasite; we observed .60%
reduction in worm burden and a decrease in worm eggs trapped in
liver. The induction of high-level protection was related to the
native proteolytic activity of the peptidase as inactivation of the
enzyme with an inhibitor significantly (P,0.0001) reduced,
although did not ablate, its protective activity. Moreover, the
functional C-1 peptidase derived from F. hepatica, FhCL1, was also
capable of inducing high-level anti-schistosome protective immune
responses, while its inactive variant induced significantly (P,
0.0001) lower protection levels. Therefore, these data support our
suggestion that helminth C-1 peptidases can induce protection
against S. mansoni infection in mice.
Injections of SmCB1 or FhCL1 peptidases significantly
increased the titres of antigen-specific antibody responses within
6 days after challenge infection compared to mice receiving a
schistosome infection alone. The antibodies detected in the
peptidase-immunized mice were primarily of the IgG1 and IgG2b
isotype (no IgE was detected), demonstrating that the injection of
the peptidases boosted early adaptive immune responses with
CD4+ T cell help. Furthermore, peptidase-specific cytokine
secretion, particularly the Th2 cytokines IL-4, IL-5, IL-13, was
Figure 2. Effects of immunization with SmCB or FhCL without adjuvant on immune responses, assessed 6 days post infection. (a)
Titres of peptidase specific IgG were measured in the sera of immunized mice by ELISA. The data shown is representative of 3 independent
experiments and displays the inverse of the end point serum dilution. (b) The isotype of peptidase specific antibodies in the sera of mice was
determined by ELISA. The data shown is representative of 5 independent experiments. Each column represents the delta mean absorbance 6 the
standard error around the mean (SD). (c) Spleens were harvested from mice that were infected following immunization with SmCB1 or a combination
of SmCB1 and FhCL1. The quantity of cytokine (IL-4, IL-5, IL-13 and IFN-c) released into culture media by spleen cells stimulated with SmCB1 in vitro
was measured by ELISA. Supernatants from cells incubated in media only served as negative controls. Each column represents the mean 6 SD.
doi:10.1371/journal.pone.0085401.g002
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also observed in the immunized mice at 6 days after infection but
not in the non-immunized mice. It has been previously shown that
the subcutaneous injection of several C-1 allergens, such as papain
and bromelain, produce Th2 adjuvant activity, enhancing Th2-
type responses to bystander antigens such as ovalbumin in mice
[18–20,39–41]. We suggest, therefore, that the protective immune
responses generated by peptidase injection likely result from
skewing of the immune response in a way that does not support the
development of schistosome parasites. In addition, the induction of
peptidase-specific immune responses, particularly antibodies, likely
bind and prevent the action of these essential enzymes. This latter
idea may explain why inactive SmCB1 peptidases also elicited a
low but significant level of protection. The mutant FhCL1 induced
a minimal level of protection which may be accounted for by the
induction of antibodies that cross-react with schistosome cathepsin
L peptidases.
Despite observing specific peptidase-induced immune responses
in the first week of the challenge infection these did not cause a
reduction in the number of lung-stage schistosomula implying that
parasite attrition occurs sometime after their migration from the
lung, perhaps in the liver [42], or after settlement of the parasites
in the mesenteric veins. This is interesting in the context of
previous studies suggesting that schistosomes not only promote the
differentiation of CD4+ T cells but also depend on their activity for
their successful maturation in the mesenteric veins and subsequent
egg production [43]. The pre-patent immune responses to
schistosomes is generally considered to be dominated by Th1-
responses [44], although recently de Oliveira Fraga et al. [45,46]
showed that female and males worms also induce antigen-specific
Th2 responses. Upsetting the fine balance between the Th1 and
Th2 responses in pre-patent infection in either direction, may be
sufficient to achieve protection. Consistent and high-level protec-
tion is also observed when mice are exposed to irradiated-
attenuated cercariae but, in contrast to our observations with
SmCB1 and FhCL1, this is effective against the parasites as they
migrate into the lungs and is mediated by Th1-driven responses
[42,47].
In our previous studies we showed that we could induce highly
significant (P,0.0001) reduction (60–78%) in the worm burdens
and worm egg load in liver and small intestine in mice challenged
with S. mansoni when the larval excretory-secretory antigens
SG3PDH/PRX-MAP were administered subcutaneously with
papain. Antibody and cytokine analysis confirmed that papain
was facilitating a bystander Th2-like adjuvant effect on SG3PDH/
PRX-MAP. Furthermore, the levels of protection obtained were
similar to those observed when SG3PDH/PRX-MAP was
delivered in combination with Th2-associated cytokines, TSLP,
IL-25, or IL-33 [16]. Here we showed that when SG3PDH/PRX-
MAP was combined with SmCB1, or FhCL1, we could achieve
very high levels of protection, up to 83%. The combination of
SG3PDH/PRX-MAP and parasite C-1 peptidases also exhibited a
blocking effect on lung-stage schistosomes, consistent with our
earlier findings [16] and elicited a profound reduction in eggs
trapped in the liver and intestinal tissues of the mice. These data
demonstrate the potential for other schistosome antigens to act in
synergy with the C-1 peptidases and prompt future trials using
other protective antigens that are known to target the early
migratory stages, such as IRV5 and calpain [9–13].
It is interesting to note that immunizations with SmCB1 and
FhCL1 alone or in combination with rSG3PDH/PRX-MAP did
not induce a considerable decrease in worm egg counts in the
small intestine when assessed at or before six weeks after infection
(data not shown), in support of earlier findings documenting a
correlation of Th2 dominant responses with increased production
of schistosome eggs [48,49]. However, we observed highly
significant (P,0.002) reduction in egg load at seven weeks after
infection, in contrast to vaccination with radiation-attenuated
cercariae, which induced a transient decrease in S. mansoni
fecundity that was restored to normal at eight weeks post infection
[50].
Highest (P,0.0001) reduction in challenge worm egg counts in
liver and small intestine was consistently recorded when
SG3PDH/PRX-MAP was combined with SmCB1 and FhCL1,
which likely cross-reacts with SmCL1 enzymes that possess a
reproduction-related function [24,29,51]. Therefore, in the future
is may be worthwhile examining the effect of immunization with
functional C-1 peptidase of schistosomes that are believed to be
Figure 3. Adjuvant effect of SmCB and FhCL mixture. Mice were
immunized 1x (a) or 2x (b) with rSG3PDH+PRX-MAP alone or combined
with SmCB+FhCL, and challenged 3 weeks later with 120 cercariae of S.
mansoni. Columns represent mean worm burden in 8–12 mice/group,
and vertical bars denote SD about the mean. P values and percent
reduction in worm burden and as compared to control mice are shown
above the columns of the test groups.
doi:10.1371/journal.pone.0085401.g003
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involved in a variety of functions including reproduction and
tegument biogenesis [21–27]. It has previously been shown that
treatment of S. mansoni-infected mice with an inhibitor of cysteine
peptidases led to reduction in parasite burden and pathology [52].
Using active C-1 peptidases derived from schistosomes may
offer an innovative approach to vaccine and/or adjuvant design,
especially that SmCB and FhCL failed to induce generation of
specific IgE after one or two immunizations in mice. In contrast to
the findings of Chappell et al. [53], we did not observe adverse
reactions in any immunized mouse at 6 or 7 weeks after infection.
Additionally, serum antibodies of humans infected with S, mansoni
binding to SmCB1 and FhCLwere predominantly of the IgG and
IgA isotype, in support of previous studies [53,54], providing a
barrier to potential adverse sensitization. Data shown in Figure 4
revealed that the number of patients with cysteine peptidase-
specific IgE did not differ from the number of patients responding
with IgE antibodies to SG3PDH [33]. Additionally, the cysteine
peptidase-specific IgE antibody levels were low corroborating the
findings of de Oliveira Fraga et al [46]. It is important to note that
the data shown in Figure 4 support and extend the findings
documenting the multiple specificities of schistosome antigens-
specific IgE, precluding dimerization of IgE/IgE receptors on the
surface of basophils or mast cells, and consequent allergic
reactions.
In conclusion, we report a highly effective vaccine using
functionally active cysteine peptidases in outbred mice and where
immunological correlates of resistance is associated with Th2
responses consistent with that found in humans for all three species
of schistosomes [55–58].
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Table 2. Recovery of lung-stage schistosomules from unimmunized and immunized mice 6 days after the challenge infection.
Vaccine formulation No. of mice tested No. of larvae/mouse ± SD P value
PBS (controls) 12 16.163.9 -
SmCB1 10 15.164.7 NS
FhCL1 8 15.163.1 NS
SmCB1+FhCL1 8 13.263.6 NS
SmCB1+SG3PDH/PRX MAP 6 7.563.4 0.0003*
For each experiment, lung-stage larvae were recovered from 2–3 mice per group, and counted on an individual mouse basis. Mean number 6 SD around the mean of
larvae retrieved from 2–6 repeat groups is shown. NS =not significant compared to PBS controls, as assessed using the Student 2-tailed t-test.
*Immunization of mice with SG3PDH or PRX-MAP alone or emulsified with Freund’s, alum, or Allison’ adjuvant failed to elicit changes in number of lung-stage larvae
recovered from immunized mice compared to adjuvant controls (data not shown).
doi:10.1371/journal.pone.0085401.t002
Figure 4. Human antibody isotype responses. A total of 50 patients (18–20 year-old) with confirmed schistosomiasis (100–400 eggs/gram stool)
were tested for serum antibody IgM, IgG1, IgG2 (sera diluted 1:250), IgG4, IgA1/A2, and IgE (sera diluted 1:25) reactivity to recombinant SmCB, FhCL,
or SG3PDH (250 ng/well), or SEA (1 mg/well) in duplicate wells. Patients with mean absorbance values higher than the mean absorbance values of 14
sex- and age-matched, parasite-free, control donors are considered responders.
doi:10.1371/journal.pone.0085401.g004
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